SRES-447-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent.
Sponsored by Cindy Hyde-Smith (R-MS)
What it does
This resolution designates September 25, 2025, as "National Ataxia Awareness Day." It expresses the Senate's support for raising public and medical awareness of ataxia, improving diagnosis and access to care, and accelerating research toward treatments and a cure. It also encourages states, territories, and localities to support the day's goals. The resolution carries no binding legal force, appropriates no funds, and creates no new programs or mandates.
Who benefits
The approximately 150,000 Americans living with inherited ataxia and their families, who may gain greater public recognition and awareness of their condition. Ataxia researchers and advocacy organizations, such as the National Ataxia Foundation, who may see increased public and donor attention. Healthcare providers who may become better informed about diagnosis. Patients with rare neurological diseases broadly, as awareness campaigns can support Orphan Drug Act research incentives.
Who is hurt
No group is directly harmed by this resolution. There are no mandates, spending changes, or regulatory effects. Competing rare disease advocacy groups may experience marginally reduced relative attention on the designated date, though this effect would be negligible.
Supporters argue
Supporters argue that ataxia affects tens of thousands of Americans across all age groups, yet remains poorly understood by the general public and even some healthcare providers, leading to delayed diagnoses and limited research funding. They contend that congressional recognition — as with other rare disease awareness designations — can meaningfully amplify advocacy efforts, increase patient community visibility, and encourage both public and private investment in research for conditions that currently have no approved cures.
Opponents argue
Opponents argue that symbolic resolutions consume limited congressional floor time without producing measurable health outcomes, and that the Senate has passed hundreds of similar commemorative designations with no demonstrated effect on research funding or patient care. They contend that if Congress genuinely prioritizes ataxia, it should direct resources through appropriations or Orphan Drug Act incentives rather than non-binding proclamations that carry no enforcement mechanism or funding commitment.